These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 29269255)
21. Immunoproteasome β5i-Selective Dipeptidomimetic Inhibitors. Singh PK; Fan H; Jiang X; Shi L; Nathan CF; Lin G ChemMedChem; 2016 Oct; 11(19):2127-2131. PubMed ID: 27561172 [TBL] [Abstract][Full Text] [Related]
22. Studies of C-terminal naphthoquinone dipeptides as 20S proteasome inhibitors. Scotti A; Trapella C; Ferretti V; Gallerani E; Gavioli R; Marastoni M J Enzyme Inhib Med Chem; 2016; 31(3):456-63. PubMed ID: 25942361 [TBL] [Abstract][Full Text] [Related]
23. Synthesis and Biochemical Evaluation of Warhead-Decorated Psoralens as (Immuno)Proteasome Inhibitors. Schiffrer ES; Proj M; Gobec M; Rejc L; Šterman A; Mravljak J; Gobec S; Sosič I Molecules; 2021 Jan; 26(2):. PubMed ID: 33445542 [TBL] [Abstract][Full Text] [Related]
24. Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i). Klein M; Busch M; Friese-Hamim M; Crosignani S; Fuchss T; Musil D; Rohdich F; Sanderson MP; Seenisamy J; Walter-Bausch G; Zanelli U; Hewitt P; Esdar C; Schadt O J Med Chem; 2021 Jul; 64(14):10230-10245. PubMed ID: 34228444 [TBL] [Abstract][Full Text] [Related]
25. Naphthoquinone amino acid derivatives, synthesis and biological activity as proteasome inhibitors. Marastoni M; Trapella C; Scotti A; Fantinati A; Ferretti V; Marzola E; Eleonora G; Gavioli R; Preti D J Enzyme Inhib Med Chem; 2017 Dec; 32(1):865-877. PubMed ID: 28657369 [TBL] [Abstract][Full Text] [Related]
26. Design, Synthesis, and Biological Activity of Isosyringolin A. Kitahata S; Chiba T; Yoshida T; Ri M; Iida S; Matsuda A; Ichikawa S Org Lett; 2016 May; 18(9):2312-5. PubMed ID: 27123978 [TBL] [Abstract][Full Text] [Related]
27. Development of peptidomimetic boronates as proteasome inhibitors. Micale N; Ettari R; Lavecchia A; Di Giovanni C; Scarbaci K; Troiano V; Grasso S; Novellino E; Schirmeister T; Zappalà M Eur J Med Chem; 2013 Jun; 64():23-34. PubMed ID: 23639651 [TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and biological evaluation of triaryl compounds as novel 20S proteasome inhibitors. Yang Y; Wang K; Wu B; Yang Y; Lai F; Chen X; Xiao Z Bioorg Med Chem Lett; 2020 Nov; 30(21):127508. PubMed ID: 32853683 [TBL] [Abstract][Full Text] [Related]
29. [Research progress on selective immunoproteasome inhibitors]. Kong L; Lu J; Zhu H; Zhang J Zhejiang Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 48(6):688-694. PubMed ID: 31955545 [TBL] [Abstract][Full Text] [Related]
30. 20S proteasome as novel biological target for organochalcogenanes. Piovan L; Milani P; Silva MS; Moraes PG; Demasi M; Andrade LH Eur J Med Chem; 2014 Feb; 73():280-5. PubMed ID: 24463395 [TBL] [Abstract][Full Text] [Related]
31. Cell-based screening of extracts of natural sources to search for inhibitors of the ubiquitin-proteasome system and identification of proteasome inhibitors from the fungus Remotididymella sp. Nishimura S; Hitora Y; Kawahara T; Tanabe M; Ogata E; Kato H; Srikoon P; Watanabe T; Tsukamoto S Bioorg Med Chem Lett; 2022 Mar; 59():128566. PubMed ID: 35063633 [TBL] [Abstract][Full Text] [Related]
32. Total synthesis and absolute stereochemistry of the proteasome inhibitors cystargolides A and B. Tello-Aburto R; Hallada LP; Niroula D; Rogelj S Org Biomol Chem; 2015 Oct; 13(40):10127-30. PubMed ID: 26400369 [TBL] [Abstract][Full Text] [Related]
34. Search for Inhibitors of the Ubiquitin-Proteasome System from Natural Sources for Cancer Therapy. Tsukamoto S Chem Pharm Bull (Tokyo); 2016; 64(2):112-8. PubMed ID: 26833439 [TBL] [Abstract][Full Text] [Related]
35. ONX 0914 Lacks Selectivity for the Cardiac Immunoproteasome in CoxsackievirusB3 Myocarditis of NMRI Mice and Promotes Virus-Mediated Tissue Damage. Neumaier HL; Harel S; Klingel K; Kaya Z; Heuser A; Kespohl M; Beling A Cells; 2020 Apr; 9(5):. PubMed ID: 32354159 [No Abstract] [Full Text] [Related]
36. Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer's Disease. Lee MJ; Bhattarai D; Jang H; Baek A; Yeo IJ; Lee S; Miller Z; Lee S; Hong JT; Kim DE; Lee W; Kim KB J Med Chem; 2021 Aug; 64(15):10934-10950. PubMed ID: 34309393 [TBL] [Abstract][Full Text] [Related]
37. Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability. Ladi E; Everett C; Stivala CE; Daniels BE; Durk MR; Harris SF; Huestis MP; Purkey HE; Staben ST; Augustin M; Blaesse M; Steinbacher S; Eidenschenk C; Pappu R; Siu M J Med Chem; 2019 Aug; 62(15):7032-7041. PubMed ID: 31283222 [TBL] [Abstract][Full Text] [Related]
38. Discovery of Natural Proteasome Inhibitors as Novel Anticancer Therapeutics: Current Status and Perspectives. Wang H; Yang Q; Dou QP; Yang H Curr Protein Pept Sci; 2018 Feb; 19(4):358-367. PubMed ID: 28079010 [TBL] [Abstract][Full Text] [Related]
39. Omuralide and vibralactone: differences in the proteasome- β-lactone-γ-lactam binding scaffold alter target preferences. List A; Zeiler E; Gallastegui N; Rusch M; Hedberg C; Sieber SA; Groll M Angew Chem Int Ed Engl; 2014 Jan; 53(2):571-4. PubMed ID: 24285701 [TBL] [Abstract][Full Text] [Related]
40. Modulation of proteasome subunit selectivity of syringolins. Tatsumi K; Kitahata S; Komatani Y; Katsuyama A; Yakushiji F; Ichikawa S Bioorg Med Chem; 2024 May; 106():117733. PubMed ID: 38704960 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]